Most often genetic variations of Type-I tumors are KRAS and BRAF mutations that activate the mitogen-activated protein kinase (MAPK) signaling pathway [ 19– 219.
Codons 12 and 61 are 'hotspots' for mutations that activate their malignant transforming properties.
In c-H-ras, c-K-ras, and c-N-ras, codons 12 and 61 are 'hotspots' for mutations that activate their malignant transforming properties [1], [2], [3].
We therefore designed a genetic screen to search for novel cytoprotective features of the autophagy-lysosome pathway by looking for mutations that activate the pathway as a signaling or defense response.
Medulloblastomas, embryonal tumors arising in the cerebellum, commonly contain mutations that activate Wnt signaling.
The point mutations that activate the PIK3CA have been observed in some gliomas [ 18].
This region comprises the sites of the abx/bx mutations that activate Ubx expression in PS5 and more posterior parasegments.
Such approaches have begun to bridge the gap between prognosis signatures and the underlying, driver mutations that activate them.
It is likely that other inhibitors of synaptic transmission can be identified by screening for mutations that activate this normally silent synapse.
It has been suggested that the point mutations that activate the PI3KCA gene may represent a novel mechanism for the induction oncogenic PI3K signaling pathway [ 14, 15].
